Relapsed/Refractory Acute Myeloid Leukemia
Conditions
Sponsors
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Clinically diagnosed patients with relapsed refractory acute myeloid leukemia (R/R AML) (2) Age: 18-60 years old; (3) no serious damage to the function of major organs of the whole body; (4) No history of drug allergy in the program (5) Participants planning to become pregnant must agree to use contraception before entering the study and after six months of study duration; Notify the investigator immediately if the subject is pregnant or suspected to be pregnant; (6) The subject understands and signs the informed consent;
Exclusion criteria
Exclusion criteria: (1) Confirmed diagnosis of acute myeloid leukemia type M3; (2) 60 years old; (3) There are basic diseases of important organs: such as myocardial infarction, chronic cardiac insufficiency, decompensated liver insufficiency, renal function, gastrointestinal insufficiency, etc. (4) Clinically uncontrolled active infections (including bacterial, fungal, or viral infections) that do not respond to medical treatment; (5) Participating in other clinical studies, or plan to start this study treatment less than 4 weeks from the end of the previous clinical study treatment (6) Patients with other malignant tumors requiring treatment; (7) Allergy to the drugs in the program; (8) The female subject is pregnant or lactating; (9) Human immunodeficiency virus (HIV) infection or syphilis infection; (10) Active hepatitis that remains uncontrolled after active antiviral therapy (positive for hepatitis B virus deoxyribonucleic acid [HBV DNA] or hepatitis C virus RNA [HCV RNA]); (11) Persistent COVID-19 positive patients (excluding positive patients who have turned negative); (12) Circumstances that the investigator believes may increase the risk to the subject or interfere with the test results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall response rate;transplantation rate;Overall survival;Relapse free survival;MRD negative rate; | — |
Countries
China
Contacts
Public ContactDonghua Zhang
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed